To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)

This study has been completed.

Sponsor:

Information provided by:

Nanjing University School of Medicine

ClinicalTrials.gov Identifier:

NCT00518219

First received: August 16, 2007

Last updated: May 25, 2010

Last verified: March 2009

History of Changes

Purpose

The purpose of this study is to assess the efficacy of TW compared to Valsartan in treatment of heavy proteinuria of membranous nephropathy.

Condition	Intervention	Phase
Membranous Nephropathy	Drug: TW	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	To Compare the Efficacy and Safety of TW vs Valsartan in the MN

Resource links provided by NLM:

MedlinePlus related topics: Kidney Diseases

Drug Information available for: Valsartan

Genetic and Rare Diseases Information Center resources: Membranous Nephropathy Glomerulonephritis

U.S. FDA Resources

Further study details as provided by Nanjing University School of Medicine:

Primary Outcome Measures:

To access the efficacy of TW compared to ARB in treatment of heavy proteinuria of membranous nephropathy [ Time Frame: 12 months ]

Secondary Outcome Measures:

To investigate the safety and tolerability of TW vs ARB in treatment of MN [ Time Frame: 12 months ]


Enrollment:	68
Study Start Date:	July 2007
Study Completion Date:	September 2009
Primary Completion Date:	March 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: immunosuppressor TW 120mg/d，Valsartan,160mg/d	Drug: TW TW,120mg/d Other Name: TW,Tripterygium wilfordii Hook.f

Detailed Description:

Membranous nephropathy with heavy proteinuria have high risks of progressing to CRF.

Tripterygium (TW) is a Chinese traditional patent drugs, it can reduce proteinuria of chronic glomerular nephritis,such as IgA nephropathy. So, we designed this randomized, prospective clinical trial to assess the efficacy and safety of TW versus Valsartan in the treatment of heavy proteinuria of MN.

Eligibility


Ages Eligible for Study:	18 Years to 65 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Biopsy-proven idiopathic membranous nephropathy
Nephrotic syndrome with proteinuria (> 4 g/day) and serum albumin < 30 g/dl
Age over 18 with informed consent

Exclusion Criteria:

Patient with abnormal liver function tests
Prior therapy with sirolimus, CSA, MMF, tacrolimus or azathioprin, chlorambucil, levamisole, methotrexate, or nitrogen mustard in the last 90 days,
Active/serious infection,
Patient with hepatitis B surface antigen or who is hepatitis C antibody positive

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00518219

Locations


China, Jiangsu
Research Institute of Nephrology
Nanjing, Jiangsu, China, 210002

Sponsors and Collaborators

Nanjing University School of Medicine

Investigators


Principal Investigator:	Zhihong Liu, Master	Jinling Hospital, China

More Information


Responsible Party:	Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing University School of Medicine
ClinicalTrials.gov Identifier:	NCT00518219 History of Changes
Other Study ID Numbers:	NJCT-0702
Study First Received:	August 16, 2007
Last Updated:	May 25, 2010

Keywords provided by Nanjing University School of Medicine:


TW Valsartan treatment membranous nephropathy proteinuria

Additional relevant MeSH terms:


Kidney Diseases Glomerulonephritis, Membranous Urologic Diseases Glomerulonephritis Nephritis Autoimmune Diseases	Immune System Diseases Valsartan Antihypertensive Agents Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 25, 2017

To Top